证券代码：000881 证券简称：中广核技 公告编号：2024-058 中广核核技术发展股份有限公司 关于公司参与投资的产业基金完成私募投资基金备 案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 中广核核技术发展股份有限公司（以下简称"公司"或"中广核技"）近日 收到基金管理人中广核产业投资基金管理有限公司通知，公司参与绵阳市政府发 起设立的产业基金绵阳白鹭核技股权投资基金合伙企业（有限合伙）（以下简称 "合伙企业"）已在中国证券投资基金业协会完成备案，具体情况如下： 一、投资概述 公司于2021年10月15日召开的2021年第二次临时股东大会审议通过了《关 于出资白鹭科技城（绵阳）核技术应用产业发展基金和参与设立白鹭科技城（绵 阳）产融管理有限公司的决策申请议案》，2023 年 10 月 26 日召开的第十届董事 会第十一次会议审议通过了《关于出资设立核技术基金产融公司决策申请的议 案》，公司拟参与绵阳市政府发起设立的绵阳白鹭核技股权投资基金合伙企业（有 限合伙），基金主要投资于民用核技术领域的应用、核医学行业及其上下游相关 行业、加速器应用领域 ...

中广核核技术发展股份有限公司 关于部分股票期权注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 中广核核技术发展股份有限公司（以下简称"公司"或"中广核技"）于 2024 年 8 月 28 日召开的第十届董事会第十九次会议及第十届监事会第十次会议审议 通过了《关于注销首期第一个行权期及离职人员股票期权的议案》，董事会同意 6 名离职人员已获授但尚未行权的股票期权共计 87 万份予以注销；因 2023 年度 公司未完成业绩考核目标，对所有首批授予及预留授予的激励对象所持有的第一 个行权期已获授的股票期权共 230 名激励对象股票期权共计 769.6614 万份予以 注销。详见公司于 2024 年 8 月 30 日在《证券时报》及巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于 2022 年股票期权激励计划第一个行权 期行权条件未成就及注销部分股票期权的公告》（公告编号 2024-054）。 证券代码：000881 证券简称：中广核技 公告编号：2024-057 特此公告。 中广核核技术发展股份有限公司 董事会 2024 ...

Investment Rating - The report does not explicitly state an investment rating for Cgn Nuclear Technology Development (000881 CH) Core Views - The company's profit loss narrowed year-on-year in 2024H1, with operating income of 2.828 billion yuan, a decline of 1.26% year-on-year, and a net loss of 86.5778 million yuan, an increase of 18.56% year-on-year [1][3] - The primary reasons for the continued loss include underperformance in the new materials business and losses from incubation period businesses, with the new materials business profit decreasing by 35 million yuan year-on-year [1][2] - The company successfully completed the proton therapy equipment manufacturing base, marking a significant milestone in domestic production capabilities [2][3] Summary by Sections Financial Performance - In 2024H1, the company reported operating income of 2.828 billion yuan, a year-on-year decline of 1.26%, and a net loss of 86.5778 million yuan, which is an increase of 18.56% year-on-year [1][3] - In Q2 2024, total operating income was 1.518 billion yuan, a quarter-on-quarter increase of 15.88%, but a year-on-year decline of 7.30% [1][3] - The gross profit margin for Q2 2024 was 13.69%, reflecting a quarter-on-quarter increase of 2.49 percentage points and a year-on-year increase of 1.69 percentage points [1][3] Business Segments - Electron accelerator and irradiation processing achieved operating income of 186 million yuan, an increase of 18.34% year-on-year, with a gross profit margin of 31.44% [2][3] - New materials segment reported operating income of 2.282 billion yuan, a year-on-year increase of 5%, but with a gross profit margin of 9.44%, down 2.70 percentage points [2][3] - Import and export trade saw a significant decline in revenue, down 71.90% year-on-year, while ocean shipping revenue decreased by 5.10% year-on-year [2][3] Market Position and Growth - The company maintained a leading market share in the domestic industrial electron accelerator sector, with a 12.08% increase in sales contract value year-on-year [2][3] - New order volume in irradiation processing increased by 25.43% year-on-year, with over 100 new irradiation customers acquired [2][3] - The company has developed 12 special incremental products targeting blank markets in mature products, with significant growth in the "three new" market segment [2][3] Innovation and Development - In 2024H1, the company was granted 39 new invention patents and completed the construction of the proton therapy equipment manufacturing base, which is the first domestic commercial proton therapy system localization base [2][3] - The company is actively promoting the Yangtze River Delta Innovation Center for nuclear technology, focusing on key research projects such as proton medical equipment [2][3]

第十届董事会第十九次会议决议公告 1.中广核核技术发展股份有限公司（以下简称"公司"或"中广核技"）第 十届董事会第十九次会议（以下简称"本次会议"）通知于 2024 年 8 月 18 日以 电子邮件形式发出。 证券代码：000881 证券简称：中广核技 公告编号：2024-050 中广核核技术发展股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 一、董事会会议召开情况 2.本次会议于 2024 年 8 月 28 日 15:30 在温州市中广核俊尔新材料有限公司 研发中试楼多功能厅以现场及通讯表决相结合的方式召开。 3.本次会议应出席董事 9 名，实际出席并参与表决董事 9 名，其中，董事李 勇、何祖元、牟文君、慕长坤、吴远明，独立董事孙光国、康晓岳现场出席会议， 其他董事以通讯方式参加会议。 4.本次会议由董事长李勇先生召集并主持。公司三名监事、董事会秘书及部 分高管人员列席会议。 5.本次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件 和《公司章程》的规定。 二、董事会会议审议情况 经出席会议的董事审议和表决，本次会议形成以下决 ...

中广核核技术发展股份有限公司 关于中广核财务有限责任公司的风险评估报告 根据深圳证券交易所于 2023 年 1 月 13 日发布的《深圳证券交易所上市公司 自律监管指引第 7 号—交易与关联交易（2023 年修订）》的要求，以及中广核财 务有限责任公司（以下简称"财务公司"）提供的有关资料和财务报表，中广核 核技术发展股份有限公司（以下简称"公司"）对财务公司截至 2024 年 6 月 30 日的经营资质、业务和风险状况进行了评估，现将公司关于财务公司的风险评估 情况报告如下： 一、财务公司基本情况 财务公司成立于 1997 年 7 月 22 日，系经中国人民银行银复[1997]244 号文 批准设立的非银行金融机构，初始注册资本为人民币 3 亿元。由中国广东核电集 团有限公司(2013 年 4 月 26 日更名为中国广核集团有限公司，以下简称"中广 核")、广东核电投资有限公司、岭澳核电有限公司、广东核电服务总公司(后更 名为中广核服务集团有限公司)、广东核电实业开发有限公司、广东核电物业发 展有限公司、中广核大唐置业有限公司及中广核电进出口有限公司分别出资 61%、 10%、6%、5%、5%、5%、5%和 ...

中广核核技术发展股份有限公司 2024 年上半年非经营性资金占用及其他关联资金 往来情况汇总表 单位：万元 | 非经营性资金占 | | 占用方与上市公司的 | 上市公司核 | 2024 年期初 | 2024 年 | 1-6 月 | 年 2024 1-6 月往来 | 2024 1-6 | 年 月偿 | 2024 月 30 | 年 6 日往 | 占用形 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 资金占用方名称 | | 算的会计科 | 往来资金余 | 往来累计发生金 | | 资金的利 | | | | | | 占用性质 | | 用 | | 关联关系 | | | | | | 还累计发 | | 来资金余 | | 成原因 | | | | | | 目 | 额 | 额（不含利息） | | 息（如 有） | 生金额 | | 额 | | | | | | 北京广利核系统工程有限 | 受最终控制方控制的 | 应收账款 | 22.08 | | 40.31 | | | 22.08 | | 40. ...

证券代码：000881 证券简称：中广核技 公告编号：2024-053 中广核核技术发展股份有限公司 关于拟续聘会计师事务所的公告 立信会计师事务所 2023 年度业务收入 50.01 亿元，其中审计业务收入 35.16 亿元，证券业务收入 17.65 亿元。2023 年度立信会计师事务所为 671 家上市公司 提供年报审计服务，审计收费 8.32 亿元。为本公司同行业 45 家上市公司提供审 计服务，具有上市公司所在行业审计业务经验。 2.投资者保护能力 截至 2023 年末，立信会计师事务所已提取职业风险基金 1.66 亿元，购买的 职业保险累计赔偿限额为 12.50 亿元，相关职业保险能够覆盖因审计失败导致的 民事赔偿责任。 近三年在执业行为相关民事诉讼中承担民事责任的情况： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 一、拟续聘会计师事务所的基本情况 （一）机构信息 1.基本信息 立信会计师事务所（特殊普通合伙）（以下简称"立信会计师事务所"）由 我国会计泰斗潘序伦博士于 1927 年在上海创建，1986 年复办，2010 年成为全国 首家完成改 ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 2,827,618,524.81, a decrease of 1.26% compared to CNY 2,863,683,121.86 in the same period last year[12]. - The net profit attributable to shareholders was CNY -86,577,822.95, showing an improvement of 17.29% from CNY -104,676,970.24 in the previous year[12]. - The cash flow from operating activities was CNY 114,323,633.95, down 48.42% from CNY 221,643,677.25 year-on-year[12]. - Basic earnings per share improved to CNY -0.0916, a 17.25% increase from CNY -0.1107 in the same period last year[12]. - Total revenue for the reporting period was approximately CNY 2.83 billion, with a net loss of CNY 87 million, a slight narrowing of losses compared to the previous year[37]. - The company reported a significant focus on proton therapy systems for tumor treatment, utilizing high-energy proton beams to minimize damage to surrounding healthy tissues, enhancing treatment precision and reducing side effects[28]. - The company achieved a year-on-year increase of 12.08% in sales contract amounts across its business segments, despite a mild decline in the existing market[32]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 11,174,022,032.64, a decrease of 0.97% from CNY 11,283,404,643.67 at the end of the previous year[12]. - The net assets attributable to shareholders were CNY 5,501,795,031.58, down 1.51% from CNY 5,586,012,022.44 at the end of the previous year[12]. - Cash and cash equivalents at the end of the reporting period amounted to CNY 1,091,886,329.48, representing 9.77% of total assets[41]. - The company reported a decrease in inventory to CNY 1,090,350,565.36, which is 9.76% of total assets[41]. - The company's total liabilities decreased slightly to CNY 5,233,382,373.00 from CNY 5,253,602,360.01, a reduction of about 0.4%[133]. Revenue Segments - Revenue from new materials reached CNY 2,281,548,034.36, accounting for 80.69% of total revenue, with a year-on-year increase of 5.00%[39]. - The import and export trade segment saw a significant decline in revenue to CNY 38,016,993.22, down 71.90% from CNY 135,285,583.90 in the previous year[39]. - Revenue from overseas markets increased by 1.34% to CNY 153,393,001.86, while domestic revenue decreased by 1.40% to CNY 2,674,225,522.95[40]. Research and Development - Research and development expenses amounted to approximately CNY 122.25 million, a decrease of 5.66% compared to the previous year[38]. - The company has achieved a total of 39 invention patents, 28 utility model patents, and 18 software copyrights in the first half of 2024, reflecting its commitment to innovation[31]. - The company is advancing its research and development efforts in proton therapy and irradiation technology, with a focus on domestic production and innovation[31]. Market and Business Strategy - The company is engaged in market expansion through the development of high-energy linear accelerators and low-energy linear accelerators for various industrial applications[18]. - The company emphasizes a sales-driven production model, particularly in the new materials sector, to meet market demands[20]. - The company has established partnerships with downstream enterprises in sectors such as agriculture, healthcare, and electronics for its irradiation processing services[19]. Financial Management and Investments - The company has maintained a focus on prudent financial management despite the termination of the acquisition deal[46]. - The total amount raised from the non-public offering of shares was CNY 2,799,999,963.66, with a net amount of CNY 2,755,135,673.06 after deducting fees[50]. - The company has utilized idle raised funds to purchase principal-protected financial products amounting to CNY 196,000,000.00 during the reporting period[51]. Environmental and Social Responsibility - The company has successfully served over 50 local agricultural processing enterprises, providing processing services for approximately 2,800 tons of agricultural products[88]. - The company actively participated in rural revitalization efforts, purchasing approximately 450,000 yuan worth of local specialty agricultural products[89]. - The company has established emergency response plans for environmental incidents and conducted drills to enhance response capabilities[84]. Corporate Governance - The company held three shareholder meetings in 2024, with participation rates of 41.91%, 47.36%, and 49.95% respectively[71]. - The company has made significant changes in its board and supervisory roles, including the election of new non-independent directors and supervisors[72][73]. - The company has implemented a comprehensive reform plan with 75 key tasks aimed at enhancing productivity and governance from 2023 to 2025[67]. Legal and Compliance - The company reported no significant penalties or rectification measures during the reporting period[95]. - The company has not reported any overdue amounts or impairment provisions related to entrusted financial management[117]. - The company has not engaged in any significant contracts during the reporting period[117].

为出具本法律意见书之目的，本所委派律师（以下简称"本所律师"）列席了贵 公司本次股东会，并根据有关中国法律、法规的规定及要求，按照律师行业公认的 业务标准、道德规范和勤勉尽责精神，对贵公司提供的与本次股东会召开有关的文 深圳市福田区中心四路 1-1 号 嘉里建设广场第三座第 2803-04 室 邮编：518048 电话：(86-755) 2939-5288 传真：(86-755) 2939-5289 junhesz@junhe.com 北京市君合（深圳）律师事务所 关于中广核核技术发展股份有限公司 2024 年第三次临时股东会的法律意见书 致：中广核核技术发展股份有限公司 北京市君合（深圳）律师事务所（以下简称"本所"）受中广核核技术发展股份 有限公司（以下简称"贵公司"或"公司"）的委托，就贵公司 2024 年第三次临时股东 会（以下简称"本次股东会"）召开的有关事宜，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》、《上市公司股东大会规则》（以下 简称"《股东大会规则》"）等中国现行法律、法规和规范性文件（以下简称"中国法 律、法规"，为本法律意见书之目的，"中国"不包括 ...

证券代码：000881 证券简称：中广核技 公告编号：2024-048 中广核核技术发展股份有限公司 关于召开 2024 年半年度业绩说明会并征集相关 问题的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 中广核核技术发展股份有限公司（以下简称"公司"）定于 2024 年 8 月 30 日披露公司《2024 年半年度报告》。为进一步加强与广大投资者的沟通交流，公 司计划召开 2024 年半年度业绩说明会，现将有关事项公告如下： 一、说明会类型 四、公司出席人员 党委书记、董事长李勇，党委副书记、董事、总经理盛国福，独立董事孙光 国，党委委员、总会计师杨凌浩，董事会秘书杨新春。 五、问题征集 本次业绩说明会将以网络文字交流的形式召开，公司将主要围绕 2024 年半 年度业绩及经营情况与投资者进行交流，在信息披露允许的范围内答复投资者普 遍关注的问题。 二、召开时间 2024 年 8 月 30 日（星期五）15:30—16:30。 三、参与方式 投资者可于 2024 年 8 月 30 日登录深圳市路演中网络科技有限公司网站（会 议链接：https://ww ...